6-METHYL-2-(PYRROLIDIN-1-YL)PYRIMIDIN-4-AMINE
![]() |
- $130 - $3998
- Product name: 6-METHYL-2-(PYRROLIDIN-1-YL)PYRIMIDIN-4-AMINE
- CAS: 1247645-16-4
- MF: C9H14N4
- MW: 178.23
- EINECS:
- MDL Number:MFCD16690458
- Synonyms:6-METHYL-2-(PYRROLIDIN-1-YL)PYRIMIDIN-4-AMINE;6-Methyl-2-pyrrolidin-1-yl-pyrimidin-4-ylamine;6-Methyl-2-(1-pyrrolidinyl)-4-pyrimidinamine;4-Pyrimidinamine, 6-methyl-2-(1-pyrrolidinyl)-
4 prices
Selected condition:
Brand
- AK Scientific
- Chemenu
- Crysdot
- TRC
Package
- 50mg
- 250mg
- 1g
- ManufacturerAK Scientific
- Product number3597AJ
- Product description6-Methyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine
- Packaging250mg
- Price$1032
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM167125
- Product description6-Methyl-2-pyrrolidin-1-ylpyrimidin-4-amine 97%
- Packaging1g
- Price$489
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11316586
- Product description6-Methyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine 97%
- Packaging1g
- Price$518
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberM221838
- Product description6-Methyl-2-(Pyrrolidin-1-Yl)pyrimidin-4-amine
- Packaging50mg
- Price$130
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AK Scientific | 3597AJ | 6-Methyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine | 250mg | $1032 | 2021-12-16 | Buy |
Chemenu | CM167125 | 6-Methyl-2-pyrrolidin-1-ylpyrimidin-4-amine 97% | 1g | $489 | 2021-12-16 | Buy |
Crysdot | CD11316586 | 6-Methyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine 97% | 1g | $518 | 2021-12-16 | Buy |
TRC | M221838 | 6-Methyl-2-(Pyrrolidin-1-Yl)pyrimidin-4-amine | 50mg | $130 | 2021-12-16 | Buy |
Properties
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|